chufangao/CTO huggingface dataset:
Clinical trial NCT03662659: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Official title: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 274.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-16
Primary completion date: 2020-08-27
Completion date: 2024-01-18
Clinical trial NCT02407990: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
Official title: A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 451.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-02
Primary completion date: 2020-08-12
Completion date: 2020-08-12
Plan to share individual participant data: YES
Clinical trial NCT03728426: Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Official title: A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-11
Primary completion date: 2022-03-28
Completion date: 2022-03-28
Limitations and caveats: This study did not reach the target number of participants needed to achieve target power and statistically reliable results. The study was closed early due to difficulty in recruiting during the COVID-19 pandemic.
Plan to share individual participant data: NO
Clinical trial NCT04097301: Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
Official title: A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6
Sponsor: AGC Biologics S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Inability to close the study in a clinically relevant time frame
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-27
Primary completion date: 2021-06-18
Completion date: 2021-06-18
Baseline population: Overall, 8 patients were enrolled in the study and underwent the screening phase to evaluate the compliance to the clinical inclusion / exclusion criteria as well as the CD44v6 expression by tumor cells (Table 10).~Of the 8 enrolled patients, 2 were treated with MLM-CAR44.1 T-cell at the first dose level. Five patients were screening failures and 1 patient dropped-out before lymphocyte apheresis for fulminant disease progression.
Limitations and caveats: The early termination of this study is due to the analysis of its feasibility, based on the low patient recruitment rate (due to the lower-than-expected proportion of myeloma and leukemia expressing the CD44v6). A further decrease in the recruitment occurred with the diffusion of the COVID-19 emergency and the availability of new drugs for the treatment of myeloma and leukemia. These reasons make impossible to foresee the conclusion of the study in a clinically relevant time frame.
Clinical trial NCT02893332: Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)
Official title: Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma
Acronym: Sindas
Sponsor: Sichuan Provincial People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: After interim analysis, IRB recommend termination.
Enrollment: 200.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-01-15
Primary completion date: 2020-08-30
Completion date: 2020-08-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03345849: A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
Acronym: U-EXCEL
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 526.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-07
Primary completion date: 2021-10-15
Completion date: 2022-01-13
Baseline population: Intention-to-treat (ITT) population for the 12-week double-blind induction period includes all randomized participants who received at least one dose of double-blind study drug during Part 1.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT04073472: Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's
Official title: A Phase I Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch
Acronym: IPAAF
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: This clinical trial was entered in error. Please refer to the correct entry of this study using the following link: https://clinicaltrials.gov/ct2/show/NCT04519684
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-01
Primary completion date: 2022-06-01
Completion date: 2023-06-01
Plan to share individual participant data: NO
Clinical trial NCT04684394: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
Official title: A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy
Sponsor: Gemini Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-29
Primary completion date: 2022-01-10
Completion date: 2022-02-18
Baseline population: The Full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug (GEM103 or sham).
Plan to share individual participant data: NO
Clinical trial NCT04427306: Neoadjuvant T-VEC in High Risk Early Melanoma
Official title: Biomarker Analysis of Neoadjuvant Intralesional Therapy in High Risk Early Melanoma
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: low enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-21
Primary completion date: 2022-06-27
Completion date: 2024-05-21
Plan to share individual participant data: NO
Clinical trial NCT02956785: What After the First Propess
Official title: What After the First Propess. A Randomised Comparative Prospective Study
Acronym: PRODUCT
Sponsor: South Warwickshire NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inability to recruit more women because of the COVID-19 and staffing/resources issues
Enrollment: 85.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-01-31
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Clinical trial NCT04668235: Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)
Official title: Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial
Sponsor: HRH Pharmaceuticals Limited (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-23
Primary completion date: 2022-08-10
Completion date: 2022-08-10
Plan to share individual participant data: NO
Clinical trial NCT03783403: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Official title: A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed.
Enrollment: 206.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-01
Primary completion date: 2024-08-05
Completion date: 2024-08-05
Clinical trial NCT05429762: Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
Official title: Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors
Acronym: TusaRav-QT
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.
Enrollment: 56.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-03
Primary completion date: 2023-08-01
Completion date: 2024-04-10
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03814187: Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
Official title: An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C
Acronym: ORION-8
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3275.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-16
Primary completion date: 2023-02-13
Completion date: 2023-02-13
Baseline population: Demographic and baseline characteristics are based on the safety population, as primary and secondary analysis are based on the safety population.~The safety population consisted of all ORION-3 rollover subjects who signed the informed consent to Study ORION-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study ORION-8
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03730077: FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas
Official title: Integrated Biomarker PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas Using a Novel PET/CT Tracer
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: PI Left Institution
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-01
Primary completion date: 2021-02-18
Completion date: 2021-02-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02565901: Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Official title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated due to insufficient funding
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2020-06-16
Completion date: 2020-06-16
Clinical trial NCT03988920: A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Official title: A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE)
Acronym: NORMALIZE
Sponsor: Ardelyx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 172.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-15
Primary completion date: 2021-06-26
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT05525572: Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)
Official title: Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)
Acronym: COCKTAIL-DM
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funding ended
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-02-12
Primary completion date: 2024-08-02
Completion date: 2024-08-02
Plan to share individual participant data: NO
Clinical trial NCT05643170: An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Official title: A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Acronym: PENNANT
Sponsor: Karuna Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Company's business decision.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-08
Primary completion date: 2023-03-01
Completion date: 2023-03-08
Plan to share individual participant data: NO
Clinical trial NCT02545933: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Official title: Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study
Acronym: VORA-PRATIC
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-02-29
Primary completion date: 2019-05-31
Completion date: 2020-01-31
Clinical trial NCT04278937: Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage
Official title: Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage. A Randomized Controlled Trial
Sponsor: Ain Shams Maternity Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-15
Primary completion date: 2020-02-15
Completion date: 2020-04-15
Clinical trial NCT03245255: Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
Official title: Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-04
Primary completion date: 2020-09-18
Completion date: 2023-06-07
Plan to share individual participant data: YES
IPD sharing description: This project will generate pressure values in the aorta, and left and right ventricles using the proposed research method (i.e., SHAPE) and using the standard of care (i.e., catheter based pressure values). Additionally peripheral and central pressures will be generated. All of the pressure values will be made available. Further, all ultrasound data obtained for SHAPE measurements will be made available after anonymizing the data-set to remove any patient information
IPD time frame: 2018-08-01 (anticipated) or starting 6 months after publication
IPD access criteria: Accessible research platform
Clinical trial NCT03184584: Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Official title: An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Sponsor: Liminal BioSciences Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Terminated early due to redeployment of study site staff during Covid-19 pandemic
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-09
Primary completion date: 2020-05-08
Completion date: 2020-05-08
Clinical trial NCT03265951: Ramelteon for Complex Insomnia in Veterans With PTSD
Official title: A Pilot, Randomized, Double-blind, Placebo Controlled, Trial of Ramelteon for CPAP Non-Adherent Veterans With PTSD and Complex Insomnia
Acronym: DORMI
Sponsor: State University of New York at Buffalo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of response
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-01
Primary completion date: 2019-09-30
Completion date: 2020-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02667587: An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Official title: A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
Acronym: CheckMate548
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 716.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-09
Primary completion date: 2020-12-22
Completion date: 2024-04-09
Baseline population: Demographic characteristics are based off all randomized participants
Clinical trial NCT03526536: Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD
Official title: A Comparison of Insulin Sensitivity and Management in Hyperglycemic Patients in the Perioperative Period: ESRD vs. Non-ESRD
Sponsor: State University of New York - Downstate Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study required more participants than anticipated for statistical significance.
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-01
Primary completion date: 2020-09-03
Completion date: 2020-09-03
Plan to share individual participant data: NO
Clinical trial NCT02822144: General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke
Official title: General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke
Acronym: GASS
Sponsor: Rennes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 351.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-29
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT05061537: Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Official title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.
Enrollment: 13.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-10-20
Primary completion date: 2022-10-14
Completion date: 2022-10-14
Baseline population: Safety analysis set included all enrolled participants who received at least one dose of study intervention. Data was not collected for Part 1B and Part 2 as no participants were enrolled due to early termination.
Limitations and caveats: Data was not collected for Part 1B and Part 2 as no participants were enrolled due to early termination.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.